Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19
| Autor: | Alebai U. Sabitov, Dmitry A. Lioznov, Konstantin V. Zhdanov, Elena P. Tikhonova, Elena V. Esaulenko, Olga P. Kovtun, Pavel L. Kuznetsov, Pavel V. Sorokin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Терапевтический архив, Vol 96, Iss 5, Pp 517-522 (2024) |
| Druh dokumentu: | article |
| ISSN: | 0040-3660 2309-5342 00403660 |
| DOI: | 10.26442/00403660.2024.05.202770 |
| Popis: | Aim. To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults. Materials and methods. The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial. Results. The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established. Conclusion. As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|